These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 33901643)
21. Structural Investigation of a Dimeric Variant of Pyruvate Kinase Muscle Isoform 2. Srivastava D; Razzaghi M; Henzl MT; Dey M Biochemistry; 2017 Dec; 56(50):6517-6520. PubMed ID: 29182273 [TBL] [Abstract][Full Text] [Related]
22. Computer-aided identification of a novel pyruvate kinase M2 activator compound. Li Y; Bao M; Yang C; Chen J; Zhou S; Sun R; Wu C; Li X; Bao J Cell Prolif; 2018 Dec; 51(6):e12509. PubMed ID: 30133040 [TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies. Lei M; Feng H; Bai E; Zhou H; Wang J; Shi J; Wang X; Hu S; Liu Z; Zhu Y Bioorg Med Chem; 2018 Aug; 26(14):3975-3981. PubMed ID: 29934218 [TBL] [Abstract][Full Text] [Related]
24. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer. Wang X; Zhang H; Yang H; Bai M; Ning T; Deng T; Liu R; Fan Q; Zhu K; Li J; Zhan Y; Ying G; Ba Y Mol Oncol; 2020 Mar; 14(3):539-555. PubMed ID: 31901148 [TBL] [Abstract][Full Text] [Related]
25. Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway. Fukuda S; Miyata H; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1461-8. PubMed ID: 25808097 [TBL] [Abstract][Full Text] [Related]
26. Novel purine thioglycoside analogs: synthesis, nanoformulation and biological evaluation in in vitro human liver and breast cancer models. Abu-Zaied MA; Loutfy SA; Hassan AE; Elgemeie GH Drug Des Devel Ther; 2019; 13():2437-2457. PubMed ID: 31440030 [No Abstract] [Full Text] [Related]
27. Mechanistic and Structural Insights into Cysteine-Mediated Inhibition of Pyruvate Kinase Muscle Isoform 2. Srivastava D; Nandi S; Dey M Biochemistry; 2019 Sep; 58(35):3669-3682. PubMed ID: 31386812 [TBL] [Abstract][Full Text] [Related]
28. Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Parnell KM; Foulks JM; Nix RN; Clifford A; Bullough J; Luo B; Senina A; Vollmer D; Liu J; McCarthy V; Xu Y; Saunders M; Liu XH; Pearce S; Wright K; O'Reilly M; McCullar MV; Ho KK; Kanner SB Mol Cancer Ther; 2013 Aug; 12(8):1453-60. PubMed ID: 23720766 [TBL] [Abstract][Full Text] [Related]
29. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer. Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533 [TBL] [Abstract][Full Text] [Related]
30. Moderate DNA damage promotes metabolic flux into PPP via PKM2 Y-105 phosphorylation: a feature that favours cancer cells. Kumar B; Bamezai RN Mol Biol Rep; 2015 Aug; 42(8):1317-21. PubMed ID: 25840825 [TBL] [Abstract][Full Text] [Related]
31. Biochemical and structural insights into how amino acids regulate pyruvate kinase muscle isoform 2. Nandi S; Dey M J Biol Chem; 2020 Apr; 295(16):5390-5403. PubMed ID: 32144209 [TBL] [Abstract][Full Text] [Related]
32. Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen species. Yokoyama M; Tanuma N; Shibuya R; Shiroki T; Abue M; Yamamoto K; Miura K; Yamaguchi K; Sato I; Tamai K; Satoh K Int J Oncol; 2018 Mar; 52(3):881-891. PubMed ID: 29393401 [TBL] [Abstract][Full Text] [Related]
33. Pyruvate kinase M2: A simple molecule with complex functions. Alquraishi M; Puckett DL; Alani DS; Humidat AS; Frankel VD; Donohoe DR; Whelan J; Bettaieb A Free Radic Biol Med; 2019 Nov; 143():176-192. PubMed ID: 31401304 [TBL] [Abstract][Full Text] [Related]
34. A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2. Arora S; Joshi G; Chaturvedi A; Heuser M; Patil S; Kumar R J Med Chem; 2022 Jan; 65(2):1171-1205. PubMed ID: 34726055 [TBL] [Abstract][Full Text] [Related]
36. Dietary-phytochemical mediated reversion of cancer-specific splicing inhibits Warburg effect in head and neck cancer. Yadav S; Bhagat SD; Gupta A; Samaiya A; Srivastava A; Shukla S BMC Cancer; 2019 Nov; 19(1):1031. PubMed ID: 31675998 [TBL] [Abstract][Full Text] [Related]
37. LncCCAT1 interaction protein PKM2 upregulates SREBP2 phosphorylation to promote osteosarcoma tumorigenesis by enhancing the Warburg effect and lipogenesis. Pu F; Liu J; Jing D; Chen F; Huang X; Shi D; Wu W; Lin H; Zhao L; Zhang Z; Lv X; Wang B; Zhang Z; Shao Z Int J Oncol; 2022 Apr; 60(4):. PubMed ID: 35244192 [TBL] [Abstract][Full Text] [Related]
38. Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread. Giannoni E; Taddei ML; Morandi A; Comito G; Calvani M; Bianchini F; Richichi B; Raugei G; Wong N; Tang D; Chiarugi P Oncotarget; 2015 Sep; 6(27):24061-74. PubMed ID: 26183399 [TBL] [Abstract][Full Text] [Related]
39. Glycolytic reprogramming in cancer cells: PKM2 dimer predominance induced by pulsatile PFK-1 activity. Shi X; You L; Luo RY Phys Biol; 2019 Sep; 16(6):066007. PubMed ID: 31469100 [TBL] [Abstract][Full Text] [Related]
40. Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. Zhu S; Guo Y; Zhang X; Liu H; Yin M; Chen X; Peng C Cancer Lett; 2021 Apr; 503():240-248. PubMed ID: 33246091 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]